Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy.

Sharon L GardnerRohinton S TaraporeJeffrey AllenSusan L McGovernWafik ZakyYazmin OdiaDoured DaghistaniZuanel DiazMatthew D HallZiad KhatibCarl J KoschmannEvan CantorRyo KurokawaTobey J MacDonaldDolly AguileraNicholas A VitanzaSabine MuellerCassie KlineGuangrong LuJoshua E AllenSoumen Khatua

Published in: Neuro-oncology advances (2022)

The adult 625 mg weekly RP2D of ONC201 scaled by body weight was well tolerated. Further investigation of ONC201 for DMG/DIPG is warranted.

Keyphrases

body weight
high grade
early stage
study protocol
open label
clinical trial
phase iii
low grade
radiation therapy
phase ii
locally advanced
radiation induced
childhood cancer
randomized controlled trial
young adults
rectal cancer